Cited by 216Pancreatic function and diabetesDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.

Open access

Cavaghan, M K, Ehrmann, D A, Byrne, M M, Polonsky, K S·1997·Journal of Clinical Investigation

DOI 10.1172/jci119562PMC PMC508219

Open this paper in CoChat — free account Open PDF

Abstract

Impaired glucose tolerance (IGT) is associated with defects in both insulin secretion and action and carries a high risk for conversion to non-insulin-dependent diabetes mellitus (NIDDM).Troglitazone, an insulin sensitizing agent, reduces glucose concentrations in subjects with NIDDM and IGT but is not known to affect insulin secretion.We sought to determine the role of ␤ cell function in mediating improved glucose tolerance.Obese subjects with IGT received 12 wk of either 400 mg daily of troglitazone ( n ϭ 14) or placebo ( n ϭ 7) in a randomized, double-blind design.Study measures at baseline and after treatment were glucose and insulin responses to a 75-g oral glucose tolerance test, insulin sensitivity index (S I ) assessed by a frequently sampled intravenous glucose tolerance test, insulin secretion rates during a graded glucose infusion, and ␤ cell glucose-sensing ability during an oscillatory glucose infusion.Troglitazone reduced integrated glucose and insulin responses to oral glucose by 10% ( P ϭ 0.03) and 39% ( P ϭ 0.003), respectively.S I increased from 1.3 Ϯ 0.3 to 2.6 Ϯ 0.4 ϫ 10 Ϫ 5 min Ϫ 1 pM Ϫ 1 ( P ϭ 0.005).Average insulin secretion rates adjusted for S I over the glucose interval 5-11 mmol/liter were increased by 52% ( P ϭ 0.02), and the ability of the ␤ cell to entrain to an exogenous oscillatory glucose infusion, as evaluated by analysis of spectral power, was improved by 49% ( P ϭ 0.04).No significant changes in these parameters were demonstrated in the placebo group.In addition to increasing insulin sensitivity, we demonstrate that troglitazone improves the reduced ␤ cell response to glucose characteristic of subjects with IGT.This appears to be an important factor in the observed improvement in glucose tolerance.( J. Clin.Invest.1997.100: 530-537.)Key words: thiazoles • insulin resistance • insulin secretion • non-insulin-dependent diabetes mellitus • glucose intolerance Methods SubjectsThe study design was that of a double blind, placebo-controlled clinical trial in which two subjects were assigned to treatment with troglitazone for every one subject treated with placebo.Randomization was performed by Parke-Davis Pharmaceutical Research Division, Warner Lambert Co. (Ann Arbor, MI), who kindly provided the study medication and placebo.The groups were well matched for age, degree of obesity, and extent of glucose intolerance (for all compari-

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci119562

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Spectral Analysis and its Applications.
Freiberger, W. F., Jenkins, G. M., & Watts, D. G. (1969) · Journal of the American Statistical Association · doi:10.2307/2286100 · Cited by 4,990
An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,645
Immunoassay of Insulin: Two Antibody System: Plasma Insulin Levels of Normal, Subdiabetic and Diabetic Rats
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,197
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose
Bergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640
Physical activity and reduced occurrence of non–insulin-dependent diabetes mellitus
Helmrich, S. P., Ragland, D. R., Leung, R. W., & Paffenbarger, R. S. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250302 · Cited by 1,634
Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise The 6-year Malm� feasibility study
Eriksson, K. F., & Lindg�rde, F. (1991) · Diabetologia · doi:10.1007/bf00400196 · Cited by 1,092
Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents
Warram, J. H., Martin, B. C., Krolewski, A. S., Soeldner, J. S., & Kahn, C. R. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-12-909 · Cited by 1,038
Diabetes Mellitus: Report of a WHO Study Group.
(1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-4-597_2 · Cited by 1,030
Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B. H., Beerdsen, P., Joyce, M., & Olefsky, J. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 914
Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 887
Self-citation
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807
Glucose Toxicity
Rossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 774
Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle.
Zhou, Y. P., & Grill, V. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117042 · Cited by 677
Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance
Cauter, E. V., Mestrez, F., Sturis, J., et al. (1992) · Diabetes · doi:10.2337/diabetes.41.3.368 · Cited by 643
Predictors of Progression From Impaired Glucose Tolerance to NIDDM: An Analysis of Six Prospective Studies
Edelstein, S. L., Knowler, W. C., Bain, R. P., Andres, R., Barrett-Connor, E. L., Dowse, G. K., Haffher, S. M., Pettitt, D. J., Sorkin, J. D., Muller, D. C., et al. (1997) · Diabetes · doi:10.2337/diab.46.4.701 · Cited by 641
Banting lecture 1990. Beta-cells in type II diabetes mellitus
Porte, D. (1991) · Diabetes · doi:10.2337/diab.40.2.166 · Cited by 599
Impaired Glucose Tolerance as a Disorder of Insulin Action
Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567
Self-citation
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
Dunaif, A. E., Scott, D., Finegood, D. T., Quintana, B., & Whitcomb, R. W. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784087 · Cited by 561
Impaired Pulsatile Secretion of Insulin in Relatives of Patients with Non-Insulin-Dependent Diabetes
O'Rahilly, S., Turner, R. C., & Matthews, D. R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181902 · Cited by 540
Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats
Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., & Horikoshi, H. (1988) · Diabetes · doi:10.2337/diab.37.11.1549 · Cited by 474
Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome
Dunaif, A. E., & Finegood, D. T. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772555 · Cited by 457
Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.
Ehrmann, D. A., Sturis, J., Byrne, M. M., Karrison, T., Rosenfield, R. L., & Polonsky, K. S. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118064 · Cited by 426
Self-citation
Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects
Suter, S. L., Nolan, J. J., Wallace, P., Gumbiner, B. M., & Olefsky, J. M. (1992) · Diabetes Care · doi:10.2337/diacare.15.2.193 · Cited by 419
Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat.
Stein, D. T., Esser, V., Stevenson, B. E., Lane, K. E., Whiteside, J. H., Daniels, M. B., Chen, S., & McGarry, J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118727 · Cited by 371
A 48-hour Lipid Infusion in the Rat Time-Dependently Inhibits Glucose-Induced Insulin Secretion and B Cell Oxidation Through a Process Likely Coupled to Fatty Acid Oxidation*
Sako, Y., & Grill, V. (1990) · Endocrinology · doi:10.1210/endo-127-4-1580 · Cited by 370
Prehepatic Insulin Production in Man: Kinetic Analysis Using Peripheral Connecting Peptide Behavior*
EATON, R. P., ALLEN, R. C., SCHADE, D. S., ERICKSON, K. M., & STANDEFER, J. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-520 · Cited by 363
β-Cell Dysfunction Induced by Chronic Hyperglycemia: Current Ideas on Mechanism of Impaired Glucose-Induced Insulin Secretion
Leahy, J. L., Bonner‐Weir, S., & Weir, G. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.442 · Cited by 360
Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.
Polonsky, K. S., Licinio-Paixao, J., Given, B. D., Pugh, W., Rue, P., Galloway, J., Karrison, T., & Frank, B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112308 · Cited by 359
Self-citation
Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., Palmer, J. P., et al. (1993) · Diabetes · doi:10.2337/diabetes.42.11.1663 · Cited by 328
Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations.
Byrne, M. M., Sturis, J., Clément, K., Vionnet, N., Pueyo, M. E., Stoffel, M., Takeda, J., Passa, P., Cohen, D., & Bell, G. I. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117064 · Cited by 299
Self-citation
Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment
Kosáka, K., Kuzuya, T., Akanuma, Y., & Hagura, R. (1980) · Diabetologia · doi:10.1007/bf01228297 · Cited by 239
Increased Insulin Concentrations in Nondiabetic Offspring of Diabetic Parents
Haffner, S. M., Stern, M. P., Hazuda, H. P., Mitchell, B. D., & Patterson, J. K. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811173192001 · Cited by 238
Characterization of Seven C-peptide Antisera
FABER, O. K., Binder, C., Markussen, J., Hedïng, L. G., Naithani, V. K., Kuzuya, H., BLIX, P. M., Horwitz, D. L., & Rubenstein, A. H. (1978) · Diabetes · doi:10.2337/diab.27.1.s170 · Cited by 230
Weight Loss in Severely Obese Subjects Prevents the Progression of Impaired Glucose Tolerance to Type II Diabetes: A longitudinal interventional study
Long, S. D., O’Brien, K. D., MacDonald, K. G., Leggett-Frazier, N., Swanson, M. S., Pories, W. J., & Caro, J. F. (1994) · Diabetes Care · doi:10.2337/diacare.17.5.372 · Cited by 219
Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diabetes.38.12.1512 · Cited by 215
Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM
Iwamoto, Y., Kuzuya, T., Matsuda, A., Awata, T., Kumakura, S., Inooka, G., & Shiraishi, I. (1991) · Diabetes Care · doi:10.2337/diacare.14.11.1083 · Cited by 193
Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
Iwamoto, Y., Kosáka, K., Kuzuya, T., Akanuma, Y., Shigeta, Y., & Kaneko, T. (1996) · Diabetes Care · doi:10.2337/diacare.19.2.151 · Cited by 178
Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research
Polonsky, K. S. (1995) · Diabetes · doi:10.2337/diab.44.6.705 · Cited by 164
Self-citation
Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats
Fujiwara, T., Yoshioka, S., Yoshioka, T., et al. (1988) · Diabetes · doi:10.2337/diabetes.37.11.1549 · Cited by 160
Banting lecture 1990. Beta-cells in type II diabetes mellitus
Porte, D. (1991) · Diabetes · doi:10.2337/diabetes.40.2.166 · Cited by 150
The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia
Vague, P., & Moulin, J.-P. (1982) · Metabolism · doi:10.1016/0026-0495(82)90125-1 · Cited by 146
Chronic perifusion of rat islets with palmitate suppresses glucose- stimulated insulin release
Elks, M. L. (1993) · Endocrinology · doi:10.1210/endo.133.1.8319569 · Cited by 139
Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells.
Ibrahimi, A., Teboul, L., Gaillard, D., Amri, E., Ailhaud, G. P., Young, P. W., Cawthorne, M. A., & Grimaldi, P. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09853-0 · Cited by 137
Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus.
O'Meara, N. M., Sturis, J., Van Cauter, E., & Polonsky, K. S. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116560 · Cited by 132
Self-citation
Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone
Sreenan, S., Sturis, J., Pugh, W., Burant, C., & Polonsky, K. S. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.4.e742 · Cited by 125
Self-citation
Improvement of Insulin Secretion but Not Insulin Resistance after Short Term Control of Plasma Glucose in Obese Type II Diabetics*
Hidaka, H., NAGULESPARAN, M., Klimeś, I., Clark, R. L., Sasaki, H., Aronoff, S. L., Vasquez, B., Rubenstein, A. H., & Unger, R. H. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-2-217 · Cited by 109
Disordered metabolism in diabetes: Have we underemphasized the fat component?
McGarry, J. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240550005 · Cited by 107
Entrainment of pulsatile insulin secretion by oscillatory glucose infusion.
Sturis, J., Cauter, E. V., Blackman, J. D., & Polonsky, K. S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115015 · Cited by 106
Self-citation
Non-insulin-dependent diabetes mellitus: Interplay between B-cell inadequacy and insulin resistance
Weir, G. C. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90321-7 · Cited by 104
Insulin secretion and clearance during low-dose graded glucose infusion
Byrne, M. M., Sturis, J., & Polonsky, K. S. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.268.1.e21 · Cited by 97
Self-citation
Effect of Troglitazone on Insulin Sensitivity and Pancreatic β-Cell Function in Women at High Risk for NIDDM
Berkowitz, K. M., Peters, R. K., Kjos, S. L., Goico, J., Marroquin, A., Dunn, M. E., Xiang, A. H., Azen, S. P., & Buchanan, T. A. (1996) · Diabetes · doi:10.2337/diab.45.11.1572 · Cited by 95
Peroxisome proliferator-activated receptors A link between endocrinology and nutrition?
Keller, H., & Wahli, W. (1993) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(93)90048-j · Cited by 81
Glucose Toxicity*
Yki‐Järvinen, H. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-3-415 · Cited by 70
Elevated plasma glucose 2 h postchallenge predicts defects in beta-cell function
Byrne, M. M., Sturis, J., Sobel, R., & Polonsky, K. S. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.4.e572 · Cited by 61
Self-citation
Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, Liver Glycogen synthase activity, and β-oxidation in fructose-fed rats
Inoue, I., Takahashi, K., Katayama, S., Harada, Y., Negishi, K., Itabashi, A., & Ishii, J. (1995) · Metabolism · doi:10.1016/0026-0495(95)90085-3 · Cited by 45
Chronic perifusion of rat islets with palmitate suppresses glucose- stimulated insulin release
Elks, M. L. (1993) · Endocrinology · doi:10.1210/en.133.1.208 · Cited by 41
Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research
Polonsky, K. S. (1995) · Diabetes · doi:10.2337/diabetes.44.6.705 · Cited by 39
Self-citation
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM
Berkowitz, K., Peters, R., Kjos, S. L., Goico, J., Marroquin, A., Dunn, M. E., Xiang, A., Azen, S., & Buchanan, T. A. (1996) · Diabetes · doi:10.2337/diabetes.45.11.1572 · Cited by 34
Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat
Sturis, J., Pugh, W. L., Tang, J., & Polonsky, K. S. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.4.e786 · Cited by 32
Self-citation
Insulin Secretory Defect in Zucker fa/fa Rats Is Improved by Ameliorating Insulin Resistance
de Souza, C. J., Yu, J. H., Robinson, D. D., Ulrich, R. G., & Meglasson, M. D. (1995) · Diabetes · doi:10.2337/diab.44.8.984 · Cited by 31
Short Administration of Metformin Improves Insulin Sensitivity in Android Obese Subjects with Impaired Glucose Tolerance
Scheen, A. J., Letiexhe, M. R., & Lefèbvre, P. J. (1995) · Diabetic Medicine · doi:10.1111/j.1464-5491.1995.tb00410.x · Cited by 27
Inducers of adipose conversion activate transcription promoted by a peroxisome proliferators response element in 3T3-L1 cells
Brandes, R., Arad, R., & Bar‐Tana, J. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02082-9 · Cited by 21
Will Sulfonylurea Treatment of Impaired Glucose Tolerance Delay Development and Complications of NIDDM?
Melander, A., Bitzén, P.-O., Sartor, G., Scherstén, B., & Wahlin‐Boll, E. (1990) · Diabetes Care · doi:10.2337/diacare.13.3.53 · Cited by 10
Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance
de Souza, C. J., Yu, J. H., Robinson, D. D., et al. (1995) · Diabetes · doi:10.2337/diabetes.44.8.984 · Cited by 7

Sorted by citations

Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Thiazolidinediones
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Oral Antihyperglycemic Therapy for Type 2 Diabetes
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
The Insulin-Related Ovarian Regulatory System in Health and Disease
Poretsky, L., Cataldo, N. A., Rosenwaks, Z., & Giudice, L. C. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0374 · Cited by 852

See all 216

Authors: Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S.
Affiliations: University of Chicago (US)
ORCID: Byrne, M M
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 1997-08-01
Volume: 100
Issue: 3
Pages: 530-537
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci119562
PMC: PMC508219
OpenAlex: W2085390992
Cited by: 216
References: 63
Citations by year: 2026: 4 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 3 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 3 · 2013: 2 · 2012: 5
FWCI: 10.73
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5k08dk002315-02)
National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: troglitazone, impaired glucose tolerance, beta-cell function, insulin secretion, insulin sensitivity, insulin resistance, type 2 diabetes, glucose tolerance, thiazolidinediones, oral glucose tolerance test, insulin sensitivity index, insulin secretion rate, type 2 diabetes prevention, insulin sensitizers
MeSH terms: Troglitazone, Administration, Oral, Adult, Animals, Chromans, Double-Blind Method, Female, Glucose, Glucose Tolerance Test, Guinea Pigs, Humans, Hypoglycemic Agents, Islets of Langerhans, Male, Middle Aged, Thiazoles, Treatment Outcome, Glucose Intolerance, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks